ALPN
Leading the Next Evolution of Immunotherapies
1
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward- looking statements are not based on historical fact and include statements regarding Alpine's platform technology, potential therapies, potential milestone and royalty payments, future development plans, clinical and regulatory objectives and the timing thereof, expectations regarding the sufficiency of cash to fund operations through 2023, expectations regarding the plans of its collaborators, expectations of future collaborations, and expectations regarding the potential efficacy and commercial potential of Alpine's and its collaborator's product candidates. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may", "will", "should", "would", "expect", "plan", "intend", and other similar expressions among others. These forward-looking statements are based on current assumptions involving risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: Alpine's programs may not advance into the clinic or result in approved products on a timely or cost-effective basis or at all; Alpine may not achieve additional milestone payments pursuant to its collaborations; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, Alpine undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
"SIP" and "TIP," and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.
2
Leading the Next
Evolution of
Immunotherapies
With a Highly Productive
Directed Evolution
Platform
Acazicolcept (ALPN-101)
Dual Costimulation
Antagonist
Systemic Lupus
Erythematosus
Partnered with Phase 2
ALPN-202
Conditional CD28
Costimulator and Dual
Checkpoint Inhibitor
Immuno-oncology
Phase 1
ALPN-303
Dual B Cell
Cytokine Antagonist
Phase 1
Start Targeted 2021
3
Acazicolcept (ALPN-101)
Autoimmune/Inflammatory Diseases:
Dual CD28/ICOS Antagonist
4
Acazicolcept (ALPN-101): A First-In-Class Dual CD28/ICOS Antagonist
For Multiple Inflammatory Disease Indications
Current therapeutics block only the CD28 pathway
APC/B cell
CD80/86
CTLA4-lg*(B7)
ICOSL
ICOS
CD28
T cell
T-cell
________________
activation
* Orencia 2019 Sales were $3B (Source: BMS)
Acazicolcept (ICOSL vlgD-Fc) blocks both CD28 and ICOS pathways
APC/B cell
Acazicolcept
Acazicolcept
CD80/86
ICOSL
(B7)
CD28
ICOS
Acazicolcept inhibits T cell and
T cell
T-Dependent B cell activation
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Disclaimer
Alpine Immune Sciences Inc. published this content on 08 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 October 2021 20:31:07 UTC.